Biomarker testing for lysosomal diseases: A technical standard of the American College of Medical Genetics and Genomics (ACMG)
Biomarker-testing-lysosomal-diseases
Learn More
The ACMG and ACMG Foundation Announce New 2025-2029 Strategic Plans
The ACMG and ACMG Foundation Announce New 2025-2029 Strategic Plans
Learn More
Points to consider for providing expert witness testimony for the specialty of medical genetics: A statement of the American College of Medical Genetics and Genomics (ACMG)
Expert-Witness-Testimony-Points
Learn More
Trofinetide approved for children and adults with Rett syndrome (RTT): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)
Trofinetide-approved-for-children-and-adults-with-Rett-syndrome-RTT
Learn More
Myotonic dystrophy type 1 testing, 2024 revision: A technical standard of the American College of Medical Genetics and Genomics (ACMG)
Myotonic-dystrophy-2024-revision
Learn More
Consideration of disease penetrance in the selection of secondary findings gene-disease pairs: A policy statement of the American College of Medical Genetics and Genomics (ACMG)
Secondary-Findings-Penetrance-Policy
Learn More
Laboratory testing for preconception/prenatal carrier screening: A technical standard of the American College of Medical Genetics and Genomics (ACMG)
Preconception-Prenatal-Carrier-Screening
Learn More
Velmanase alfa approved for treatment of non-central nervous system manifestations of alpha-mannosidosis: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)
Velmanase-Alfa-Approved
Learn More
Addendum: Points to consider in the reevaluation and reanalysis of genomic test results: A statement of the American College of Medical Genetics and Genomics (ACMG)
Addendum-reevaluation-reanalysis
Learn More
Clinical utility of polygenic risk scores for embryo selection: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG)
Polygenic-Risk-Score-Testing-Embryo-Selection
Learn More